These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23232549)

  • 1. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol.
    Caldarola G; Sollena P; Peris K; De Simone C
    J Dermatol; 2015 Jul; 42(7):753-4. PubMed ID: 25899558
    [No Abstract]   [Full Text] [Related]  

  • 3. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis.
    Li X; Zhao Z; Sun SS
    Am J Health Syst Pharm; 2017 May; 74(9):e183-e192. PubMed ID: 28438823
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ponzo MG; Miliszewski M; Kirchhof MG; Keown PA; Dutz JP
    J Cutan Med Surg; 2019; 23(6):595-601. PubMed ID: 31378082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
    Zineh I; Mummaneni P; Lyndly J; Amur S; La Grenade LA; Chang SH; Rogers H; Pacanowski MA
    Pharmacogenomics; 2011 Dec; 12(12):1741-9. PubMed ID: 22118056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
    Dainichi T; Uchi H; Moroi Y; Furue M
    Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
    [No Abstract]   [Full Text] [Related]  

  • 9. HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
    Gonçalo M; Coutinho I; Teixeira V; Gameiro AR; Brites MM; Nunes R; Martinho A
    Br J Dermatol; 2013 Sep; 169(3):660-5. PubMed ID: 23600531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population.
    Niihara H; Kaneko S; Ito T; Sugamori T; Takahashi N; Kohno K; Morita E
    J Dermatol Sci; 2013 Aug; 71(2):150-2. PubMed ID: 23669020
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
    van Nguyen D; Chu HC; Vidal C; Fulton RB; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Chu HH; Thanh Thuc HT; Minh Le HT; van Nunen S; Anderson J; Fernando SL
    Pharmacogenomics; 2021 Jan; 22(1):1-12. PubMed ID: 33356553
    [No Abstract]   [Full Text] [Related]  

  • 12. HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study.
    Cheng L; Xiong Y; Qin CZ; Zhang W; Chen XP; Li J; Zhou HH
    Br J Dermatol; 2015 Aug; 173(2):555-8. PubMed ID: 26104483
    [No Abstract]   [Full Text] [Related]  

  • 13. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HLA-B58.01 and allopurinol hypersensitivity renal vasculitis in a Chinese patient].
    Mariette F; Scarfoglière V; Giot M; Basire A; Rouby F; Daniel L; Jourde-Chiche N
    Rev Med Interne; 2022 Jul; 43(7):436-439. PubMed ID: 35606203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.
    Kang HR; Jee YK; Kim YS; Lee CH; Jung JW; Kim SH; Park HW; Chang YS; Jang IJ; Cho SH; Min KU; Kim SH; Lee KW;
    Pharmacogenet Genomics; 2011 May; 21(5):303-7. PubMed ID: 21301380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
    Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
    Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.
    Park HJ; Kim YJ; Kim DH; Kim J; Park KH; Park JW; Lee JH
    Yonsei Med J; 2016 Jan; 57(1):118-26. PubMed ID: 26632391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions.
    Kano Y; Hirahara K; Asano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(6):616-8. PubMed ID: 19002350
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
    Yu KH; Yu CY; Fang YF
    Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening.
    Fernando SL; Broadfoot AJ
    CMAJ; 2010 Mar; 182(5):476-80. PubMed ID: 19933789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.